CardioClasp Inc.
This article was originally published in Start Up
Executive Summary
David Melvin, MD, a cardiac transplant surgeon who started and built the heart transplant program at the University Hospital, Cincinnati, took a sabbatical in 1991 to research and invent devices for congestive heart failure. His efforts resulted in several patented devices, among them the CardioClasp. CardioClasp is a simple, passive device that is designed to surround a patient's failing heart, to geometrically remodel it and correct for the pathological increase in size that congestive heart failure causes.
You may also be interested in...
The Failing Heart
Looking for larger patient populations, the newer CHF device companies position their products as early intervention tools that can perhaps delay or halt the progression of the disease.
CardioEnergetics Inc.
David Melvin, MD, a cardiovascular surgeon turned biomedical engineer has created a large patent portfolio of cardiac devices and components covering novel solutions to sticky problems. CardioEnergetics was founded to commercialize his current and future inventions. The company's lead product is a ventricular assist device that lies outside the blood path to avoid clotting and stroke.
CardioEnergetics Inc.
David Melvin, MD, a cardiovascular surgeon turned biomedical engineer has created a large patent portfolio of cardiac devices and components covering novel solutions to sticky problems. CardioEnergetics was founded to commercialize his current and future inventions. The company's lead product is a ventricular assist device that lies outside the blood path to avoid clotting and stroke.